SLC27A1 and melanoma: A study by the Memorial Sloan Kettering Cancer Center shows that treatment with an Inhibitor targeting FATP can block lipid transport into melanoma cells, thereby reducing melanoma cell growth and infection (Zhang et al., 2018).